A Medical Device Maker's Guide to FDA Cybersecurity Testing for 510(k) & PMA

Q: What must FDA cybersecurity testing cover for a 510(k) or PMA submission?

The FDA does not publish a single checklist, but its guidance, Section 524B, and reviewer expectations point to three testing categories a submission should address: hardware interface testing, software and firmware testing, and communication interface testing. Each category needs documented answers to specific questions, and the whole test must be grounded in a threat model and software bill of materials that were established before testing began.

Q: What must be in place before an FDA pen test even starts?

Two foundations must exist before testing: a documented threat model and a complete software bill of materials. FDA reviewers evaluate pen test evidence in the context of both. A test run without a documented threat model reads as a box-checking exercise, and a test run without a complete SBOM raises the question of whether the tester actually knew what they were testing. The credibility of the evidence depends on this foundation.

Q: Why is communication interface testing where the most serious findings appear?

Because most connected medical devices depend heavily on their communication paths, and those paths carry the highest-impact weaknesses. Communication interface testing covers wireless protocol security, such as Bluetooth pairing and Wi-Fi authentication, and TLS implementation, verifying that certificate validation is enforced, weak cipher suites are rejected, and the device resists downgrade attacks. For many devices, this is the category that surfaces the findings reviewers care about most.

Q: How closely does the FDA scrutinize device-to-backend and mobile app communication?

The FDA pays particular attention to how a device authenticates to backend systems and how it communicates with mobile applications. A device that accepts connections from any app presenting the correct device identifier, with no additional authentication, creates a patient safety risk that reviewers are specifically trained to identify. Testing must demonstrate that these connections are properly authenticated, not just functional.

Q: What must an FDA pen test evidence package contain?

The report needs more than a standard commercial findings list. It must document the scope in terms that map to the device's system security plan and threat model, map each finding to the relevant design control and risk management file entry, and document the remediation status of every finding, including any that remain open. This mapping is what lets a reviewer connect the testing to the device's overall safety and risk documentation.

Q: Do unresolved findings automatically disqualify an FDA submission?

No. Unresolved findings are not automatically disqualifying, but they require documented justification. A finding that was assessed, determined acceptable given the intended use environment and mitigating controls, and documented as an accepted risk with a compensating control is a defensible position. A finding that appears in the report with no remediation status or justification is not, and that gap is what creates a problem in review.

Contributors

Shantanoo Govilkar

SVP Strategic Solutions Risk & Cybersecurity Solutions

The rules of engagement need to reflect pharma-specific constraints that a generic pen test provider may not anticipate. No active testing on production validated systems without an approved test environment. No testing during batch manufacturing runs. Change control documentation for any activity that touches a validated system, even in a test environment. These constraints do not limit what the test can find. They ensure that what the test finds is actually actionable.

Before the Test: What Must Be in Place

A pen test submitted as FDA cybersecurity evidence is only as credible as the foundation it was built on. FDA reviewers evaluate pen test evidence in the context of the threat model and SBOM that should precede it. A test conducted without a documented threat model looks like a box-checking exercise. A test conducted without a complete SBOM raises questions about whether the tester knew what they were testing.

The threat model must reflect the device's intended use environment and the realistic threat actors relevant to that environment. A patient monitor deployed in an ICU connected to a hospital network faces threats from opportunistic attackers exploiting hospital network access, from insiders with legitimate network presence and from targeted actors interested in patient data or care disruption. The pen test methodology should be calibrated to those threats, not to a generic enterprise IT threat model.

During the Test: What Must Be Covered

FDA guidance identifies specific categories of testing that cybersecurity submissions should address. Hardware interface testing covers physical ports, debug interfaces and any physical access mechanism that could be exploited. A USB port that accepts unsigned firmware updates is a finding. An exposed JTAG interface with no access controls is a finding. These are not theoretical vulnerabilities; they are the kind of hardware-level weaknesses that have appeared in real device compromises.

Software and firmware testing covers known vulnerability validation, authentication mechanisms and update integrity. Can a malicious firmware update be installed without cryptographic verification? Can the device be accessed without valid credentials through an undocumented interface? Does the device's software contain components with known vulnerabilities that have not been patched? Each of these questions needs a documented answer in the submission.

Communication Interface Testing

For most connected devices, communication interface testing is where the most significant findings emerge. Wireless protocol testing covers Bluetooth pairing security, Wi-Fi authentication and any proprietary wireless protocol the device uses. TLS implementation testing validates that encrypted communications are actually secure: certificate validation is enforced, weak cipher suites are not accepted and the device cannot be subjected to downgrade attacks.

The FDA pays particular attention to how devices authenticate to backend systems and how they handle communication with mobile applications. A device that accepts connections from any app presenting the right device identifier without additional authentication creates patient safety risk that reviewers are trained to identify.

After the Test: What the Evidence Package Must Contain

The pen test report submitted to FDA needs to contain more than a standard commercial findings report. It needs to document the scope in terms that map to the device's SSP and threat model. It needs to map each finding to the relevant design control and risk management file entry. It needs to document the remediation status of every finding, including those that remain open with an accepted risk justification.

Unresolved findings are not automatically disqualifying, but they require documented justification. A finding that was assessed, determined to be acceptable given the intended use environment and mitigating controls, and documented as an accepted risk with a compensating control is a defensible position. A finding that appears in the report with no remediation status or justification is not.

The Patch Management Plan

Section 524B requires a postmarket patch management plan as part of the premarket submission. FDA reviewers look for evidence that the manufacturer has a realistic, tested process for monitoring vulnerabilities, assessing their relevance to specific device models and deploying patches in a timeframe proportionate to risk severity. A policy document that describes what the process will be is not the same as evidence that the process works.

Pen testing has a role in validating the patch management process as well as in the initial submission. Testing that a critical vulnerability fix actually closes the vulnerability, rather than just checking a box, is the kind of postmarket validation the FDA expects manufacturers to demonstrate capability for.

Frequently Asked Questions

What must FDA cybersecurity testing cover for a 510(k) or PMA submission? +

What must be in place before an FDA pen test even starts? +

How should the threat model be calibrated for a medical device pen test? +

What does hardware interface testing cover in an FDA submission? +

What does software and firmware testing need to answer? +

Why is communication interface testing where the most serious findings appear? +

How closely does the FDA scrutinize device-to-backend and mobile app communication? +

What must an FDA pen test evidence package contain? +

Do unresolved findings automatically disqualify an FDA submission? +

How does pen testing support the required patch management plan? +

Other Webinars

Strategies and Best Practices for Risk Assessment in AI Apps

Top 5 Reasons to Upgrade Your EDI Environment to AS4 Protocol

Enable Innovation Without the Shadow AI

Other Popular Articles

Unleashing Business Potential: The Power of Adaptive Enterprise Architecture

In the digital age, businesses must adopt an ad

15 Best Practices In Salesforce Development

Many businesses have decided to use Salesforce'

What is Governance Risk and Compliance (GRC)? A Definitive Guide

GRC is the capability, or integrated collection

Artificial Intelligence For All, Responsibly

As we look towards the turn of another year, it

Get the latest insights straight from our desk to your inbox.

What Is CMMC and Do You Need It?

Learn what CMMC is, who needs it, and how to determine if your business requires Level 1 compliance for DoD contracts.